4/16
08:00 am
ubx
Unity Biotechnology, Inc. (NASDAQ: UBX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Unity Biotechnology, Inc. (NASDAQ: UBX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.
4/15
07:10 am
ubx
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates [Yahoo! Finance]
Low
Report
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates [Yahoo! Finance]
4/15
07:00 am
ubx
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Low
Report
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
4/7
08:03 pm
ubx
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting [Yahoo! Finance]
Medium
Report
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting [Yahoo! Finance]
2/13
10:15 pm
ubx
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA [Yahoo! Finance]
Low
Report
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA [Yahoo! Finance]
2/6
08:13 am
ubx
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss [Yahoo! Finance]
Low
Report
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss [Yahoo! Finance]
2/6
08:00 am
ubx
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
Low
Report
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss